Modified-FOLFIRINOX Regimen Based Neoadjuvant Therapy in Chinese Patients With Locally Advanced Pancreatic Cancer

Overview

FOLFIRINOX regimen is first-line neoadjuvant chemotherapies for patients with locally advanced pancreatic cancer (LAPC) worldwide. However, FOLFIRINOX is not well accepted in China because of the high prevalence of adverse events and poor tolerance. To evaluate the safety and efficacy of modified-FOLFIRINOX (mFOLFIRINOX) in Chinese LAPC patients and compare survival between LAPC patients with mFOLFIRINOX-based preoperative therapy and LAPC patients who underwent surgery alone.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: November 1, 2017

Detailed Description

At this institution, a mFOLFIRINOX regimen has been adopted for metastatic pancreatic cancer (MPC) patients and promising results obtained. The modification resulted in a significantly reduced prevalence of severe adverse events in MPC patients, whereas the OS and PFS were extended to 10.3m and 7.0m, respectively, which is similar to that for patients on a full-dose regimen. Therefore, the investigators further evaluated the efficacy of mFOLFIRINOX in LAPC patients. Here, investigators want to prospectively enroll LAPC patients who underwent preoperative therapy with mFOLFIRINOX from April 2014 and compared the surgical resectability and surgical morbidity/surgical mortality among patients with surgically resectable pancreatic cancer (RPC) or LAPC who underwent surgery alone retrospectively. For patients with LAPC, mFOLFIRINOX was administrated for several cycles until the optimal response was obtained and then patients were evaluated for surgery. Moreover, survival data, including OS and PFS, were determined.

Interventions

  • Drug: modified-FOLFIRINOX
    • LAPC patients with mFOLFIRINOX-based neoadjuvant therapy or not was set as the main intervention

Arms, Groups and Cohorts

  • LAPC patients with mFOFLRINOX-based neoadjuvant therapy
    • LAPC patients were enrolled prospectively and diagnosed by MDT group in our hospital. These patients further received the neoadjuvant therapy with mFOLFIRINOX, the Overall survival, Progression survival, response to mFOLFIRINOX, chemo-related Toxicities, Postoperative complications and Histopathologic staging were measured.

Clinical Trial Outcome Measures

Primary Measures

  • Overall survival
    • Time Frame: 2014-04-01 to 2017-11-01
    • the duration from the date of hospital admission to death of any cause.
  • Progression free survival
    • Time Frame: 2014-04-01 to 2017-11-01
    • the duration from the date of hospital admission to disease progression or death.

Secondary Measures

  • Response to mFOLFIRINOX
    • Time Frame: 2014-04-01 to 2017-11-01
  • mFOLFIRINOX related adverse events
    • Time Frame: 2014-04-01 to 2017-11-01
  • Postoperative complications
    • Time Frame: 2014-04-01 to 2017-11-01
  • Histopathologic staging
    • Time Frame: 2014-04-01 to 2017-11-01

Participating in This Clinical Trial

Inclusion Criteria

1. The patients are diagnosed by histology to have pancreatic adenocarcinoma 2. The patients are defined as locally advanced pancreatic cancer according to NCCN guideline 3. The patients prescribed mFOLFIRINOX-based neoadjuvant therapy Exclusion Criteria:

1. ECOG performance score more than 2 2. Insufficient bone marrow, liver and renal function 3. Patients with other malignancies 4. Patients were older than 85 years or less than 18 years

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 85 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Second Affiliated Hospital, School of Medicine, Zhejiang University
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.